pioglitazone has been researched along with Proteinuria in 18 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 8.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| " We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)." | 7.83 | Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016) |
| "The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies." | 7.80 | Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014) |
| "Pioglitazone treatment (2." | 5.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Besides the effectiveness in blood sugar control, pioglitazone could salutarily reduce proteinuria and synthesis of TGF-beta as well as type IV collagen." | 5.12 | Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. ( Eiam-Ong, S; Katavetin, P; Suwanwalaikorn, S, 2006) |
| " Pioglitazone, a PPAR-γ agonist with a protective action on podocytes, was reported in a few cases as helpful in reducing proteinuria when combined with steroids." | 4.84 | Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy. ( Balestra, E; Barbi, E; Ceconi, V; Conversano, E; Di Maso, V; Pennesi, M, 2024) |
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 4.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| "Adriamycin-exposed rats developed proteinuria, an increased cortical HPSE and decreased heparan sulfate (HS) expression, which was ameliorated by treatment with pioglitazone." | 4.31 | Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria. ( Buijsers, B; de Graaf, M; Garsen, M; Gockeln, L; Hillebrands, JL; Kamps, JAAM; Krenning, G; Lamb, HJ; Maciej-Hulme, ML; Nijenhuis, T; Rabelink, TJ; Sol, M; Sonneveld, R; van den Born, J; van der Meer, RW; van der Vlag, J; van Kuppevelt, TH; van Raalte, DH, 2023) |
| " We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)." | 3.83 | Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016) |
| "The observed association between pioglitazone and bladder cancer could be causal or because of bias in the design of prior studies." | 3.80 | Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. ( Bilker, WB; Ferrara, A; Habel, L; Hedderson, M; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, C; Strom, BL; Vaughn, DJ, 2014) |
| "Acute podocyte injury and nephrotic syndrome were induced by puromycin aminonucleoside (PAN) injection in rats." | 3.78 | Protective effects of PPARγ agonist in acute nephrotic syndrome. ( Fogo, AB; Kon, V; Ma, LJ; Najafian, B; Potthoff, SA; Yang, HC; Zuo, Y, 2012) |
| "Pioglitazone treatment (2." | 1.38 | Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension. ( Hongo, M; Ishizaka, N; Nagai, R; Saito, K; Sakamoto, A, 2012) |
| "Our results identify hyperinsulinemia and the attendant increase of TGF-beta expression as potential therapeutic targets in diabetes independent of glycemic control." | 1.34 | Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. ( Izuhara, Y; Kakuta, T; Miyata, T; Ohtomo, S; Takizawa, S; van Ypersele de Strihou, C; Yamada, N, 2007) |
| "Treatment with pioglitazone significantly improved glucose and lipid metabolism." | 1.30 | Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. ( Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Hunley, TE | 1 |
| Hidalgo, G | 2 |
| Ng, KH | 1 |
| Shirai, Y | 1 |
| Miura, K | 1 |
| Beng, HM | 1 |
| Wu, Q | 1 |
| Hattori, M | 1 |
| Smoyer, WE | 2 |
| Garsen, M | 1 |
| Buijsers, B | 1 |
| Sol, M | 1 |
| Gockeln, L | 1 |
| Sonneveld, R | 1 |
| van Kuppevelt, TH | 1 |
| de Graaf, M | 1 |
| van den Born, J | 1 |
| Kamps, JAAM | 1 |
| van Raalte, DH | 1 |
| van der Meer, RW | 1 |
| Lamb, HJ | 1 |
| Hillebrands, JL | 1 |
| Rabelink, TJ | 1 |
| Maciej-Hulme, ML | 1 |
| Krenning, G | 1 |
| Nijenhuis, T | 1 |
| van der Vlag, J | 1 |
| Balestra, E | 1 |
| Barbi, E | 1 |
| Ceconi, V | 1 |
| Di Maso, V | 1 |
| Conversano, E | 1 |
| Pennesi, M | 1 |
| Sharma, A | 1 |
| Bourey, RE | 1 |
| Edwards, JC | 1 |
| Brink, DS | 1 |
| Albert, SG | 1 |
| Ochodnicky, P | 1 |
| Mesarosova, L | 1 |
| Cernecka, H | 1 |
| Klimas, J | 1 |
| Krenek, P | 1 |
| Goris, M | 1 |
| van Dokkum, RP | 1 |
| Henning, RH | 1 |
| Kyselovic, J | 1 |
| Lewis, JD | 1 |
| Habel, L | 1 |
| Quesenberry, C | 1 |
| Mamtani, R | 1 |
| Peng, T | 1 |
| Bilker, WB | 1 |
| Hedderson, M | 1 |
| Nessel, L | 1 |
| Vaughn, DJ | 1 |
| Strom, BL | 1 |
| Ferrara, A | 1 |
| Matsushita, K | 1 |
| Yang, HC | 2 |
| Mysore, MM | 1 |
| Zhong, J | 1 |
| Shyr, Y | 1 |
| Ma, LJ | 2 |
| Fogo, AB | 2 |
| Agrawal, S | 1 |
| Chanley, MA | 1 |
| Westbrook, D | 1 |
| Nie, X | 1 |
| Kitao, T | 1 |
| Guess, AJ | 1 |
| Benndorf, R | 1 |
| Sarafidis, PA | 1 |
| Stafylas, PC | 1 |
| Georgianos, PI | 1 |
| Saratzis, AN | 1 |
| Lasaridis, AN | 1 |
| Zuo, Y | 1 |
| Potthoff, SA | 1 |
| Najafian, B | 1 |
| Kon, V | 1 |
| Sakamoto, A | 1 |
| Hongo, M | 1 |
| Saito, K | 1 |
| Nagai, R | 1 |
| Ishizaka, N | 1 |
| Haraguchi, K | 1 |
| Shimura, H | 1 |
| Onaya, T | 1 |
| Zafiriou, S | 1 |
| Stanners, SR | 1 |
| Polhill, TS | 1 |
| Poronnik, P | 1 |
| Pollock, CA | 1 |
| Katavetin, P | 1 |
| Eiam-Ong, S | 1 |
| Suwanwalaikorn, S | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Tomasoni, S | 1 |
| Campana, M | 1 |
| Corna, D | 1 |
| Zanchi, C | 1 |
| Gagliardini, E | 1 |
| Garofano, E | 1 |
| Rottoli, D | 1 |
| Ito, T | 1 |
| Remuzzi, G | 1 |
| Omasu, F | 1 |
| Oda, T | 1 |
| Yamada, M | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Ohtomo, S | 1 |
| Izuhara, Y | 1 |
| Takizawa, S | 1 |
| Yamada, N | 1 |
| Kakuta, T | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Yoshimoto, T | 1 |
| Naruse, M | 1 |
| Nishikawa, M | 1 |
| Naruse, K | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Imaki, T | 1 |
| Demura, R | 1 |
| Aikawa, E | 1 |
| Demura, H | 1 |
1 review available for pioglitazone and Proteinuria
| Article | Year |
|---|---|
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; | 2010 |
1 trial available for pioglitazone and Proteinuria
| Article | Year |
|---|---|
Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-R | 2006 |
16 other studies available for pioglitazone and Proteinuria
| Article | Year |
|---|---|
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S | 2023 |
Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria.
Topics: Animals; Diabetes Mellitus, Type 2; Doxorubicin; Endothelial Cells; Humans; Kidney Diseases; Mice; P | 2023 |
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
Topics: Adolescent; Female; Humans; Immunosuppressive Agents; Mycophenolic Acid; Nephrotic Syndrome; Peroxis | 2024 |
Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy.
Topics: Adult; Female; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Kidney Diseases; Li | 2021 |
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Disease Progression; Doxor | 2014 |
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; California; Cohort Studies; Confounding Factors, Epidemiologic; Diab | 2014 |
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Blood Pressure; Creatinine; Diseas | 2016 |
Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.
Topics: Albuminuria; Animals; Creatinine; Cyclooxygenase 2; Drug Therapy, Combination; Glucocorticoids; Kidn | 2016 |
Protective effects of PPARγ agonist in acute nephrotic syndrome.
Topics: Actinin; Acute Disease; Animals; Antibiotics, Antineoplastic; Aquaporin 2; Blotting, Western; Cells, | 2012 |
Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Disease Models, Animal; Ferritins; Gene Expression Regulation; Heme Oxygena | 2012 |
Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Antibodies; Autoantibodies; CD8-Positive T-Lymph | 2003 |
Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.
Topics: Albumins; Animals; Biological Transport, Active; Cell Division; Cells, Cultured; Chemokine CCL2; Fib | 2004 |
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regul | 2006 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Pr | 2007 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Dia | 1997 |